Blankenhorn DH - Search Results

1

Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up.

Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Cashin-Hemphill L, et al. Among authors: blankenhorn dh. JAMA. 1990 Dec 19;264(23):3013-7. JAMA. 1990. PMID: 2243429 Clinical Trial.

2

Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures. A comparison of different measures of treatment effect.

Blankenhorn DH, Selzer RH, Mack WJ, Crawford DW, Pogoda J, Lee PL, Shircore AM, Azen SP. Blankenhorn DH, et al. Circulation. 1992 Dec;86(6):1701-9. doi: 10.1161/01.cir.86.6.1701. Circulation. 1992. PMID: 1451241

3

Comparison of computer- and human-derived coronary angiographic end-point measures for controlled therapy trials.

Mack WJ, Selzer RH, Pogoda JM, Lee PL, Shircore AM, Azen SP, Blankenhorn DH. Mack WJ, et al. Among authors: blankenhorn dh. Arterioscler Thromb. 1992 Mar;12(3):348-56. doi: 10.1161/01.atv.12.3.348. Arterioscler Thromb. 1992. PMID: 1547194 Clinical Trial.

4

Factors influencing the formation of new human coronary lesions: age, blood pressure, and blood cholesterol.

Mack WJ, Blankenhorn DH. Mack WJ, et al. Among authors: blankenhorn dh. Am J Public Health. 1991 Sep;81(9):1180-4. doi: 10.2105/ajph.81.9.1180. Am J Public Health. 1991. PMID: 1951831 Free PMC article. Clinical Trial.

5

Effects of colestipol-niacin therapy on human femoral atherosclerosis.

Blankenhorn DH, Azen SP, Crawford DW, Nessim SA, Sanmarco ME, Selzer RH, Shircore AM, Wickham EC. Blankenhorn DH, et al. Circulation. 1991 Feb;83(2):438-47. doi: 10.1161/01.cir.83.2.438. Circulation. 1991. PMID: 1991366 Clinical Trial.

6

Evaluation of human panelists in assessing coronary atherosclerosis.

Azen SP, Cashin-Hemphill L, Pogoda J, Mack WJ, Sanmarco ME, Wickham E, Blankenhorn DH. Azen SP, et al. Among authors: blankenhorn dh. Arterioscler Thromb. 1991 Mar-Apr;11(2):385-94. doi: 10.1161/01.atv.11.2.385. Arterioscler Thromb. 1991. PMID: 1998656 Clinical Trial.

7

Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors.

Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Blankenhorn DH, et al. Circulation. 1990 Feb;81(2):470-6. doi: 10.1161/01.cir.81.2.470. Circulation. 1990. PMID: 2404631 Clinical Trial.

8

The influence of diet on the appearance of new lesions in human coronary arteries.

Blankenhorn DH, Johnson RL, Mack WJ, el Zein HA, Vailas LI. Blankenhorn DH, et al. JAMA. 1990 Mar 23-30;263(12):1646-52. JAMA. 1990. PMID: 2407875 Clinical Trial.

9

Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.

Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Blankenhorn DH, et al. JAMA. 1987 Jun 19;257(23):3233-40. JAMA. 1987. PMID: 3295315 Clinical Trial.

10

Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.

Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH. Hodis HN, et al. Among authors: blankenhorn dh. Circulation. 1994 Jul;90(1):42-9. doi: 10.1161/01.cir.90.1.42. Circulation. 1994. PMID: 8026027 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

130 results

Search Page

Filters